Subtype
Pancreatic Neoplasm
CI-CAN-00001356Explore in graph →
Non-malignant987 active trials8 approved drugs63 evidence items
Loading cancer entity…
Subtype
CI-CAN-00001356Explore in graph →
Clinical trials
4,216 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06513455 | Irinotecan Liposome,Albumin Paclitaxel and Gemcitabine First-line Treatment for Pancreatic Cancer | not yet recruiting | Phase 1 / Phase 2 | 132 | Harbin Medical UniversityOTHER | 0 | Jul 22, 2024 | clinicaltrials |
| NCT06495749 | Early Diagnosis of Pancreatic Cancer Via Deciphering Multi-modal Immunological Signatures | not yet recruiting | — | 3,000 | Zhejiang UniversityOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT06492941 | A Study of Docetaxel for Injection (Albumin Bound) in Patients With Advanced Pancreatic Cancer | not yet recruiting | Phase 3 | 142 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Jul 9, 2024 | clinicaltrials |
| NCT06276738 | The LINFU® U.S. Registry in Patients With Clinical Signs and/or Symptoms of Disease | not yet recruiting | — | 1,000 | Adenocyte, LLCINDUSTRY | 0 | May 14, 2024 | clinicaltrials |
| NCT06409429 | Nimotuzumab Combined With GX as Postoperative Adjuvant Therapy in Pancreatic Cancer | not yet recruiting | Phase 2 / Phase 3 | 146 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 10, 2024 | clinicaltrials |
| NCT06329947 | A Phase II Study of Surufatinib Combined With Camrelizumab and mFOLFOX6 as Second-line Treatment for Advanced PRAD | not yet recruiting | Phase 2 | 37 | Rui-hua Xu, MD, PhDOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT06399172 | OncoSil Pancreatic Cancer Post-marketing Clinical Registry - Italy(OSPRItaly) | not yet recruiting | — | 50 | OncoSil Medical LimitedINDUSTRY | 0 | May 3, 2024 | clinicaltrials |
| NCT06375954 | EUS-guided CDS vs ERCP as First Line in Malignant Distal Obstruction in Borderline Disease (CARPEDIEM-2 Trial) | not yet recruiting | N/A | 96 | Hospital Universitari de BellvitgeOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT06370754 | Newly Emerging Immunotherapy for Pancreatic Cancer Treatment(FD-IMPACT) | not yet recruiting | Phase 1 / Phase 2 | 117 | Fudan UniversityOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT06361030 | Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer | not yet recruiting | Phase 2 | 40 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Apr 11, 2024 | clinicaltrials |
| NCT06346808 | Oncolytic Virus Plus Anti-PD1 and Chemotherapy as Preoperative Therapy for Patients With BRPC/LAPC | not yet recruiting | Phase 1 | 20 | Sichuan UniversityOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT06259058 | Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer | not yet recruiting | Phase 1 / Phase 2 | 96 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Mar 15, 2024 | clinicaltrials |
| NCT06233877 | Clinical Trial Evaluating Low Dose G-FLIP Plus Mitomycin C for Stage IV Pancreatic Cancer(GFLIPM) | not yet recruiting | Phase 2 | 60 | Hirschfeld OncologyOTHER_GOV | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06255912 | Clinical Trial for Advanced or Metastatic Pancreatic Cancer | not yet recruiting | Phase 2 | 26 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Feb 23, 2024 | clinicaltrials |
| NCT06272162 | Locally Advanced Pancreatic Cancer After Systemic Therapy: Ablative MR-guided Radiotherapy(LAPSTAR) | not yet recruiting | N/A | 150 | UMC UtrechtOTHER | 1 | Feb 22, 2024 | clinicaltrials |
| NCT06234072 | Comparing Astragalus Plus Gemcitabine to Gemcitabine Alone as Neoadjuvant Treatment for Pancreatic Cancer Patients | not yet recruiting | Phase 2 | 120 | Shenzhen University General HospitalOTHER | 1 | Feb 2, 2024 | clinicaltrials |
| NCT06217042 | HR070803 in Combination With Oxaliplatin, 5-fluorouracil/LV Versus GX as Adjuvant Therapy for Pancreatic Cancer | not yet recruiting | Phase 3 | 524 | Fudan UniversityOTHER | 1 | Jan 22, 2024 | clinicaltrials |
| NCT06210360 | Perioperative Treatment in High-risk Resectable Pancreatic Cancer With NALIRIFOX | not yet recruiting | Phase 2 | 134 | Changhai HospitalOTHER | 0 | Jan 18, 2024 | clinicaltrials |
| NCT06196658 | Early Phase I Study of Autologous T Cells (EX02 CAR-T) for Unresectable Pancreatic/Bile Duct Cancer | not yet recruiting | Early Phase 1 | 6 | Zhang Xiaofeng,MDOTHER | 0 | Jan 9, 2024 | clinicaltrials |
| NCT04889742 | Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent Tumors(HETERERO) | not yet recruiting | Phase 2 | 110 | Charite University, Berlin, GermanyOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT06172036 | Irinotecan Liposome for Resectable Pancreatic Cancer With or Without Addebelizumab(CAPT-02) | not yet recruiting | Phase 2 | 180 | Zhejiang UniversityOTHER | 0 | Dec 15, 2023 | clinicaltrials |
| NCT06166589 | Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer | not yet recruiting | Phase 2 | 19 | Shanghai Zhongshan HospitalOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT06167421 | Comparison of Kimura Versus Warshaw Technique for Laparoscopic Spleen-Preserving Distal Pancreatectomy | not yet recruiting | N/A | 240 | Fudan UniversityOTHER | 0 | Dec 12, 2023 | clinicaltrials |
| NCT06156267 | Study of Personalized Tumour Vaccines and a PD-L1 Blocker in Patients With Surgically Resected Pancreatic Adenocarcino | not yet recruiting | Early Phase 1 | 30 | Fudan UniversityOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT05810792 | Histamine Dihydrochloride and Interleukin-2 in Primary Resectable Pancreatic Cancer(PANCEP-1) | not yet recruiting | Phase 2 | 50 | Sahlgrenska University HospitalOTHER | 0 | Nov 22, 2023 | clinicaltrials |
| NCT05988372 | Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer (SAGE) | not yet recruiting | Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | Nov 1, 2023 | clinicaltrials |
| NCT06009029 | SBRT Combined With Zimberelimab (GLS-010) in Locally Advanced Pancreatic Cancer (SPARK-1 Study) | not yet recruiting | Phase 2 | 96 | Peking University Third HospitalOTHER | 0 | Aug 24, 2023 | clinicaltrials |
| NCT05903703 | Canagliflozin With Gemcitabine in Pancreatic Carcinoma | not yet recruiting | N/A | 20 | Zhang Xiaofeng,MDOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT05895214 | Mesopancreas Study in Pancreatic Cancer(MESOPANC-01) | not yet recruiting | — | 500 | Heinrich-Heine University, DuesseldorfOTHER | 1 | Jun 8, 2023 | clinicaltrials |
| NCT05361954 | Study to Assess the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Relapsed or Refractory Solid Tumors | not yet recruiting | Phase 1 | 36 | Sorrento Therapeutics, Inc.INDUSTRY | 0 | Apr 12, 2023 | clinicaltrials |
| NCT05755594 | A Prospective Study on the Safety and Efficacy of Robot-assisted Pancreaticoduodenectomy | not yet recruiting | N/A | 100 | The First Affiliated Hospital of University of South ChinaOTHER | 0 | Mar 6, 2023 | clinicaltrials |
| NCT05755607 | A Multicenter Prospective Randomized Controlled Study of RPD Versus LPD | not yet recruiting | N/A | 200 | The First Affiliated Hospital of University of South ChinaOTHER | 0 | Mar 6, 2023 | clinicaltrials |
| NCT05611359 | Surgery and Thermal Hepatic Ablation Combined With Chemotherapy in Hepatic Oligometastatic Pancreatic Cancer(HOPE-1) | not yet recruiting | N/A | 60 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 0 | Nov 10, 2022 | clinicaltrials |
| NCT05585554 | Locally Advanced Pancreatic Cancer Treated With ABLAtivE Stereotactic MRI-guided Adaptive Radiation Therapy(LAP-ABLATE) | not yet recruiting | N/A | 267 | Viewray Inc.INDUSTRY | 0 | Oct 19, 2022 | clinicaltrials |
| NCT05316480 | Nimotuzumab in EGFR Highly Expressed Pancreatic Neuroendocrine Neoplasms | not yet recruiting | Phase 2 | 42 | Fudan UniversityOTHER | 1 | Apr 7, 2022 | clinicaltrials |
| NCT05010226 | Focused Ultrasound for the Treatment of Pancreatic Cancer - an International Registry | not yet recruiting | — | 30 | National Taiwan University HospitalOTHER | 0 | Aug 18, 2021 | clinicaltrials |
| NCT04847297 | Preoperative Biliary Drainage in Malignant Biliary Obstruction(PEAR) | not yet recruiting | — | 353 | University of PecsOTHER | 0 | Apr 19, 2021 | clinicaltrials |
| NCT04707365 | Microenvironment and Immunity of Digestive Cancers - East Paris Multicentric Cohort(MICADO) | not yet recruiting | N/A | 200 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Jan 13, 2021 | clinicaltrials |
Data updated 22 days agoSource updated Jul 22, 2024source: clinicaltrials